Nexentis Technologies (NASDAQ:NXTS – Get Free Report) and Eton Pharmaceuticals (NASDAQ:ETON – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, valuation, institutional ownership, risk, earnings, dividends and profitability.
Earnings & Valuation
This table compares Nexentis Technologies and Eton Pharmaceuticals”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Nexentis Technologies | $210,000.00 | 6.10 | -$4.00 million | ($96.07) | -0.01 |
| Eton Pharmaceuticals | $105.59 million | 14.82 | -$4.60 million | $0.38 | 144.08 |
Institutional & Insider Ownership
61.2% of Nexentis Technologies shares are held by institutional investors. Comparatively, 27.9% of Eton Pharmaceuticals shares are held by institutional investors. 6.5% of Nexentis Technologies shares are held by company insiders. Comparatively, 16.5% of Eton Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Profitability
This table compares Nexentis Technologies and Eton Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Nexentis Technologies | N/A | -304.79% | -178.91% |
| Eton Pharmaceuticals | 12.02% | 40.13% | 12.37% |
Analyst Ratings
This is a summary of current ratings and recommmendations for Nexentis Technologies and Eton Pharmaceuticals, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nexentis Technologies | 1 | 0 | 0 | 0 | 1.00 |
| Eton Pharmaceuticals | 0 | 2 | 4 | 0 | 2.67 |
Eton Pharmaceuticals has a consensus price target of $67.50, indicating a potential upside of 23.29%. Given Eton Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts plainly believe Eton Pharmaceuticals is more favorable than Nexentis Technologies.
Volatility and Risk
Nexentis Technologies has a beta of 1.84, indicating that its stock price is 84% more volatile than the S&P 500. Comparatively, Eton Pharmaceuticals has a beta of 0.9, indicating that its stock price is 10% less volatile than the S&P 500.
Summary
Eton Pharmaceuticals beats Nexentis Technologies on 11 of the 14 factors compared between the two stocks.
About Nexentis Technologies
N2OFF, Inc., an agri-food tech company, engages in the development and sale of eco-friendly green solutions for the food industry to enhance food safety and shelf life of fresh produce. Its products are based on proprietary blend of food acids combined with various oxidizing agent-based sanitizers and low concentrated fungicides for cleaning, sanitizing, and controlling pathogens on fresh produce that are safer for human consumption and extend their shelf life by reducing their decay. The company’s products include SavePROTECT or PeroStar, a processing aid for post-harvest application that is added to fruit and vegetable wash water; and SF3HS and SF3H, a post-harvest cleaning and sanitizing solution to control plant and foodborne pathogens. It also offers SpuDefender for controlling post-harvest potato sprouts; and FreshProtect to control spoilage-creating microorganisms on post-harvest citrus fruit. The company was formerly known as Save Foods, Inc. and changed its name to N2OFF, Inc. in March 2024. N2OFF, Inc. was incorporated in 2009 and is headquartered in Hod HaSharon, Israel.
About Eton Pharmaceuticals
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Receive News & Ratings for Nexentis Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nexentis Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
